CD70 標靶治療的全球市場：市場機會與臨床試驗見解（2024 年）

在癌症治療的動態格局中，精準醫學的出現正在徹底改變治療模式，提供利用個別腫瘤獨特模式的客製化方法。 近年來，生物技術和製藥公司各利益相關者的好奇心因參與腫瘤發生和進展的關鍵分子啟動子的鑑定而凸顯，從一刀切的模型轉向定制的一刀切的模型。引起人們的注意。 其中，CD70蛋白已成為一個有前景的治療標靶，在癌症治療和其他治療領域具有巨大潛力。

將 CD70 作為治療標靶的研究正在擴大癌症患者更有效、個人化和客製化治療選擇的範圍。 最初，CD70 蛋白參與 T 細胞和 B 細胞的活化。 然而，臨床前研究證據顯示 CD70 蛋白會觸發磷脂□肌醇 3 激□ (PI3K) 和 MAP 激□訊號路徑的活化。 此訊號通路的活化進一步導致眾多轉錄因子的激活，從而觸發與細胞增殖和存活相關的基因的表達，從而導致癌症疾病。

透過臨床前研究提供研究證據有助於增強世界各地各利害關係人之間的信任和好奇心。 因此，許多製藥和生物技術公司計劃開發CD70療法並已開始臨床試驗。 推動 CD70 蛋白治療市場的關鍵驅動力之一是進行新穎研究的研究合作數量不斷增加。 許多公司正在與研究機構和醫院合作，以推進 CD70 治療市場。 例如，重慶精準生物科技與國內南昌大學第一附屬醫院、浙江大學、山西白求恩醫院等科研院所和醫院合作，進行剩餘的CD70臨床前和臨床研究。

Cusatuzumab (ARGX-110) 是目前最先進的 CD70 候選藥物，作為白血病治療已達到 II 期臨床階段。 除了抗CD70抗體之外，許多其他治療方法，例如CAR-T細胞療法、CAR-NK療法和針對CD70蛋白的4特異性抗體，代表了CD70療法的不斷發展的領域。 此外，隨著CD70蛋白研究的進一步進展，該領域前景廣闊，前景廣闊。

本報告檢視了全球 CD70 標靶治療市場，並提供了市場概況，包括藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司競爭格局。

目錄

第1章揭示 CD70 標靶治療的複雜性

• CD70標靶治療概述
• CD70標靶治療的歷史與發展
• CD70 標靶治療的先決條件
• CD70 作為診斷和預後生物標記的雙重作用

第 2 章 CD70 標靶治療的臨床方法

• 單株抗體
• 雙特異性抗體
• 四特異性抗體
• CAR T 細胞療法
• 抗體藥物偶聯物
• CAR-NK療法

第3章 CD70標靶治療的聯合策略

• 與免疫療法結合
• 與表觀遺傳調節劑組合
• 與標靶治療結合
• 與溶瘤病毒療法合併使用
• 與化療合併使用

第 4 章 CD70 標靶治療：當前臨床發展趨勢與創新（按適應症）

• 白血病
• 淋巴瘤
• 婦科癌症
• 腎細胞癌
• 肺癌
• 自體免疫疾病與發炎性疾病
• 病毒感染

第5章全球CD70標靶治療臨床試驗概述

• 愛別
• 依國家/地區
• 按公司
• 依指示
• 依優先權
• 患者部分

第 6 章 CD70 標靶治療候選藥物獲得 FDA 和 EMA 指定

第7章全球CD70標靶治療的當前市場趨勢與發展

• 當前市場概覽
• 未來市場預測

第 8 章 CD70 標靶治療市場機會與臨床趨勢（按地區）

• 美國
• 中國
• 歐洲

第 9 章公司與 CD70 標靶治療開發平台（按技術）

第10章全球CD70標靶治療市場動態

• 市場驅動因素
• 市場挑戰

第11章全球CD70標靶治療臨床試驗洞察

• 臨床前
• 第一階段
• 第一/二期
• 第二階段

第12章競爭態勢

• Acepodia
• Adaptimmune
• Adicet Bio
• Allogene Therapeutics
• Ambrx (Johnson & Johnson)
• Chinook Therapeutics (Novartis)
• CRISPR Therapeutics
• ImmuneOnco Biopharma
• Pfizer
• Poseida Therapeutics

Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:

• CD70 Targeting Therapies In Clinical Trials: > 20 Therapies
• CD 70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
• Insight On CD70 Targeting Therapy Technology Platforms: 6 Platforms
• FDA & EMA Designations Insight: Orphan, FTD, RMAT Designation
• Combination Stratagems for CD70 Targeting Therapies
• Insight On 10 Companies Involved In Development Of CD70 Therapies

In the dynamic landscape of cancer therapeutics, the emergence of precision medicine has transformed treatment paradigms, offering tailored approaches that take advantage of the unique patterns of individual tumors. Recently, the curiosity of various stakeholders from the biotech and pharma companies have turned the limelight from a one size fits all model to a tailored therapeutic strategy that has been underscored by the identification of key molecular drivers implicated in tumorigenesis and progression. Among these, CD70 protein has emerged as a promising therapeutic target, clenching immense potential in the realm of cancer therapy and other treatments.

The research of CD70 as a therapeutic target clenches the panorama of more effective, personalized and customized therapy choices for cancer patients. Initially, the CD70 protein was involved in T cell and B cell activation. However, augmenting evidences from preclinical studies signifies that CD70 protein causes activation of the phosphatidylinositol-3 kinase (PI3K) together with MAP kinase signaling pathways. This activation of signaling pathways further results in activation of numerous transcription factors and thereby the expression of genes involved in cell growth along with survival and causing cancer diseases.

Bestowing research evidences from preclinical studies aid to build confidence and inquisitiveness among various stakeholders across the globe. Therefore, numerous pharma and biotech companies planned to develop CD70 therapy and initiated clinical trials. One of the significant prime movers that aid to advance CD70 protein therapy market is the rise in research collaborations to conduct novel studies. Many firms are joining hands with research institute and hospitals to headway CD70 therapy market. For instance, Chongqing Precision Biotech has partnership with institutes and hospitals, including The First Affiliated Hospital of Nanchang University, Zhejiang University or Shanxi Bethune Hospital etc., in China to conduct surplus CD70 preclinical and clinical studies.

Concurrently, in the pharmaceutical sector, CD70 targeted therapeutic intervention characterize a promising revolution area. Over the preceding decennium, the sphere of global CD70 therapy market has witnessed the development of several novel, innovative as well as advanced contenders targeting CD70. For instance, candidates like SGN-CD70, bi-4SCAR GD2/ CD70 T cells, CD70 CAR-T cells, CB dualCAR- NK19/70, CTX130, CTX131, ALLO-316 and others have been developed by in the preceding years for the treatment of cancer ailments. As research and advancement expands, it is anticipated that numerous other innovative CD70 therapy will be perceived in future.

Moreover, in order to further augment the therapeutic window in conjugation with boost efficacy, pharma companies have initiated the combinational study of CD70 therapy with other therapies. Currently, a handful of combinations of CD70 therapy are being invested with immunotherapies like CAR-T therapy combination or amalgamation of CAR-T with monoclonal antibody, targeted therapies, chemotherapy, epigenetic modulators, oncolytic viruses and others. The combinational study for CD70 therapy represents a novel as well as compelling frontier in the commercial CD70 therapy landscape.

Solitary of the key characteristics which aid to amplify the sphere of CD70 targeted therapy is fostering investments and collaborations. These partnerships and investments among academic institutions, smaller biotech firms, and larger pharmaceutical companies also aid to speed up the discovery and commercialization of CD70 therapy. For instance, in February 2024, ProfoundBio has raised an investment of US$ 112 Million in Series B financing round in order to advance in its preclinical programs, including PRO1160, a CD70 targeted antibody drug conjugate.

All these examples demonstrate that the realm of CD70 therapy is burgeoning at an incredible gait. At present, US dominates the CD70 therapy segment in terms of research and development. However, China is additionally up surging and expanding the CD70 therapy arena by developing innovative CD70 candidates coupled with initiating many clinical trials. The evolutions from one size fits all model to a tailored therapeutic strategy suggests that developing CD70 therapy clenches immense potential.

Currently, Cusatuzumab (ARGX-110) is the most advanced CD70 candidates that have reached phase II clinical stage for leukemia treatment. In addition to anti-CD70 antibodies, multitudinous other therapeutic approach like CAR-T cell therapy, CAR-NK therapy or tetraspecific antibodies targeting CD70 protein represents that the domain of CD70 therapy is evolving year by year. Moreover, as research further increases for CD70 protein, the domain represents a huge prospect and a fruitful future.

Table of Contents

1. Unlocking Intricacies for CD70 Targeting Therapy

• 1.1 Overview to CD70 Targeting Therapy
• 1.2 Chronicle & Development of CD70 Targeting Therapy
• 1.3 The Prerequisite for CD70 Targeting Therapy
• 1.4 Dual Role of CD70 As Diagnostic & Prognostic Biomarker

2. Clinical Approaches For CD70 Targeting Therapy

• 2.1 Monoclonal Antibody
• 2.2 Bispecific Antibody
• 2.3 Tetraspecific Antibody
• 2.4 CAR T Cell Therapy
• 2.5 Antibody Drug Conjugate
• 2.6 CAR-NK Therapy

3. Combination Stratagems for CD70 Targeting Therapies

• 3.1 In Combination with Immunotherapy
• 3.2 In Combination with Epigenetic Modulators
• 3.3 In Combination with Targeted Therapy
• 3.4 In Combination with Oncolytic Virus Therapy
• 3.5 In Combination with Chemotherapy

4. CD70 Targeting Therapy By Indications: Current Clinical Development Trends & Innovations

• 4.1 Leukemia
• 4.2 Lymphoma
• 4.3 Gynecologic Cancer
• 4.4 Renal Cell Carcinoma
• 4.5 Lung Cancer
• 4.6 Autoimmune & Inflammatory Disease
• 4.7 Viral Infections

5. Global CD 70 Targeting Therapy Clinical Trials Overview

• 5.1 By Phase
• 5.2 By Country
• 5.3 By Company
• 5.4 By Indication
• 5.5 By Priority Status
• 5.6 Patient Segment

6. CD70 Targeting Therapy Candidates Granted FDA & EMA Designations

7. Global CD70 Targeting Therapy Current Market Trend & Developments

• 7.1 Current Market Outline
• 7.2 Future Market Forecast

8. CD70 Targeting Market Opportunity & Clinical Trends by Region

• 8.1 US
• 8.2 China
• 8.3 Europe

9. CD70 Targeting Therapy Development Platforms By Company & Technology

• 9.1 AlloCAR T Platform
• 9.2 Gamma Delta Cell Platform
• 9.3 Tailwind Platform
• 9.4 DARPin Platform
• 9.5 SIMPLE antibody platform
• 9.6 Potelligent Technology

10. Global CD70 Targeting Therapy Market Dynamics

• 10.1 Market Drivers
• 10.2 Market Challenges

11. Global CD 70 Targeting Therapies Clinical Trials Insight

• 11.1 Preclinical
• 11.2 Phase I
• 11.3 Phase I/II
• 11.4 Phase II

12. Competitive Landscape

• 12.1 Acepodia
• 12.2 Adaptimmune (TCR2 Therapeutics )
• 12.3 Adicet Bio
• 12.4 Allogene Therapeutics
• 12.5 Ambrx (Johnson & Johnson)
• 12.6 Chinook Therapeutics (Novartis)
• 12.7 CRISPR Therapeutics
• 12.8 ImmuneOnco Biopharma
• 12.9 Pfizer
• 12.10 Poseida Therapeutics

List of Figures

1. Unlocking Intricacies for CD70 Targeting Therapy

• 1.1 Overview to CD70 Targeting Therapy
• 1.2 Chronicle & Development of CD70 Targeting Therapy
• 1.3 The Prerequisite for CD70 Targeting Therapy
• 1.4 Dual Role of CD70 As Diagnostic & Prognostic Biomarker

2. Clinical Approaches For CD70 Targeting Therapy

• 2.1 Monoclonal Antibody
• 2.2 Bispecific Antibody
• 2.3 Tetraspecific Antibody
• 2.4 CAR T Cell Therapy
• 2.5 Antibody Drug Conjugate
• 2.6 CAR-NK Therapy

3. Combination Stratagems for CD70 Targeting Therapies

• 3.1 In Combination with Immunotherapy
• 3.2 In Combination with Epigenetic Modulators
• 3.3 In Combination with Targeted Therapy
• 3.4 In Combination with Oncolytic Virus Therapy
• 3.5 In Combination with Chemotherapy

4. CD70 Targeting Therapy By Indications: Current Clinical Development Trends & Innovations

• 4.1 Leukemia
• 4.2 Lymphoma
• 4.3 Gynecologic Cancer
• 4.4 Renal Cell Carcinoma
• 4.5 Lung Cancer
• 4.6 Autoimmune & Inflammatory Disease
• 4.7 Viral Infections

5. Global CD 70 Targeting Therapy Clinical Trials Overview

• 5.1 By Phase
• 5.2 By Country
• 5.3 By Company
• 5.4 By Indication
• 5.5 By Priority Status
• 5.6 Patient Segment

6. CD70 Targeting Therapy Candidates Granted FDA & EMA Designations

7. Global CD70 Targeting Therapy Current Market Trend & Developments

• 7.1 Current Market Outline
• 7.2 Future Market Forecast

8. CD70 Targeting Market Opportunity & Clinical Trends by Region

• 8.1 US
• 8.2 China
• 8.3 Europe

9. CD70 Targeting Therapy Development Platforms By Company & Technology

• 9.1 AlloCAR T Platform
• 9.2 Gamma Delta Cell Platform
• 9.3 Tailwind Platform
• 9.4 DARPin Platform
• 9.5 SIMPLE antibody platform
• 9.6 Potelligent Technology

10. Global CD70 Targeting Therapy Market Dynamics

• 10.1 Market Drivers
• 10.2 Market Challenges

11. Global CD 70 Targeting Therapies Clinical Trials Insight

• 11.1 Preclinical
• 11.2 Phase I
• 11.3 Phase I/II
• 11.4 Phase II

12. Competitive Landscape

• 12.1 Acepodia
• 12.2 Adaptimmune (TCR2 Therapeutics )
• 12.3 Adicet Bio
• 12.4 Allogene Therapeutics
• 12.5 Ambrx (Johnson & Johnson)
• 12.6 Chinook Therapeutics (Novartis)
• 12.7 CRISPR Therapeutics
• 12.8 ImmuneOnco Biopharma
• 12.9 Pfizer
• 12.10 Poseida Therapeutics